Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

This study plans to enroll participants with previously treated metastatic pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. These participants are required to experience disease progression on or after at least one prior standard systemic therapy containing fluorouracil or gemcitabine, and either progressed on or were intolerant to the last treatment. Eligible participants will be randomized 1:1 to the experimental group or the control group for treatment.

Trial Details

NCT ID
NCT07262567
Phase
PHASE3
Sponsor
Genfleet Therapeutics (Shanghai) Inc.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • GFH375
  • Chemotherapy
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Voluntarily participate in the study and sign the informed consent form.
  • Male or female aged 18-80 years (inclusive) at the time of signing the informed consent form.
  • Pathologically confirmed pancreatic cancer (derived from pancreatic ductal epithelium) at metastatic stage.
  • Have received at least one prior standard systemic therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →